Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Gains from Sales and Divestitures (2016 - 2020)

Celldex Therapeutics has reported Gains from Sales and Divestitures over the past 9 years, most recently at $1110.0 for Q4 2020.

  • Quarterly results put Gains from Sales and Divestitures at $1110.0 for Q4 2020, down 50.0% from a year ago — trailing twelve months through Dec 2020 was $1110.0 (down 50.0% YoY), and the annual figure for FY2020 was $1110.0, down 50.0%.
  • Gains from Sales and Divestitures for Q4 2020 was $1110.0 at Celldex Therapeutics, down from $2220.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for CLDX hit a ceiling of $19500.0 in Q4 2016 and a floor of $1110.0 in Q4 2020.
  • Median Gains from Sales and Divestitures over the past 5 years was $2449.0 (2018), compared with a mean of $8388.8.
  • Biggest five-year swings in Gains from Sales and Divestitures: tumbled 85.3% in 2018 and later decreased 9.35% in 2019.
  • Celldex Therapeutics' Gains from Sales and Divestitures stood at $19500.0 in 2016, then dropped by 14.54% to $16665.0 in 2017, then tumbled by 85.3% to $2449.0 in 2018, then decreased by 9.35% to $2220.0 in 2019, then crashed by 50.0% to $1110.0 in 2020.
  • The last three reported values for Gains from Sales and Divestitures were $1110.0 (Q4 2020), $2220.0 (Q4 2019), and $2449.0 (Q4 2018) per Business Quant data.